Novo Nordisk Wegovy Pill Sales Double Forecasts After Launch

Novo Nordisk delivered a first-quarter performance that fundamentally shifts the narrative around its GLP-1 portfolio, as the successful U.S. launch of its oral Wegovy pill provided a significant tailwind to top-line growth. The company reported total sales of 96.8 billion Danish kroner, a 32% increase on a constant currency basis that comfortably cleared the FactSet consensus of 71.3 billion kroner. While the headline growth is impressive, the underlying mechanics of the revenue mix reveal a transition in how the market values the company’s obesity care franchise.

The Wegovy Pill Launch Dynamics

The most critical data point from the quarter is the 2.26 billion kroner in sales generated by the Wegovy pill. This figure nearly doubled analyst estimates of 1.16 billion kroner, signaling that the oral formulation is capturing significant patient interest immediately upon entry. Novo Nordisk reported approximately 1.3 million prescriptions for the pill in the first three months of the year, characterizing the rollout as the strongest GLP-1 volume launch in U.S. history. This rapid adoption suggests that the barrier to entry for weight-loss treatments is lower for oral medications compared to the established injectable format.

Investors should note the divergence between the pill’s outperformance and the injectable Wegovy drug, which saw sales of 18,235, a 12% year-on-year increase that missed LSEG expectations. This suggests that while the total addressable market for obesity care is expanding, there is a clear shift in preference toward the convenience of the oral delivery system. The broader obesity care category reported a 22% rise in adjusted constant currency sales, confirming that the overall demand remains robust despite the mixed performance across specific delivery formats.

Margin Expansion and Accounting Tailwinds

Operating profit surged 65% year-on-year to 59.6 billion kroner, significantly outpacing the 31.7 billion kroner expected by analysts. This massive beat is partially attributed to a provision reversal related to the 340B Drug Pricing Program in the U.S. While this accounting adjustment inflated the quarterly profit figures, the underlying strength of the GLP-1 product sales remains the primary driver of the company’s improved outlook. The ability to maintain high margins while scaling a new product launch is a testament to the pricing power Novo Nordisk currently commands in the obesity care space.

It is important to contrast this with the performance of the legacy diabetes portfolio. Ozempic sales fell 8% year-on-year, though the figure still managed to exceed LSEG expectations. This decline highlights the cannibalization risk or the shifting focus of the sales force toward the higher-growth obesity care segment. For those tracking broader stock market analysis, the company’s ability to pivot its revenue base toward obesity care while managing the decline in diabetes-specific drugs is the key metric for long-term valuation.

Guidance Adjustments and Forward Risks

Novo Nordisk updated its 2026 full-year guidance, now projecting adjusted sales to contract by -4% to -12% on a currency-adjusted basis, with operating profit growth expected in the same range. This guidance reflects a cautious outlook on the sustainability of the current growth trajectory as the company navigates potential supply chain constraints and the competitive landscape for GLP-1 treatments. The shift in guidance suggests that management is factoring in the high base effect of the current quarter and the potential for increased regulatory scrutiny on drug pricing.

For investors evaluating the sector, the primary risk remains the execution of the supply chain to meet the demand for the Wegovy pill. If the company cannot maintain the current prescription volume, the valuation premium currently assigned to the stock may face downward pressure. Conversely, if the oral pill continues to gain market share at the expense of competitors, the current guidance may prove conservative. The company's performance in the coming quarters will confirm whether the pill launch is a sustainable growth engine or a temporary spike in volume.